Skip to content

Cumberland Pharmaceuticals Inc.: 10-Q filed 2024-08-09

What Cumberland Pharmaceuticals Inc. reported in its quarterly report filed 2024-08-09 (fiscal Q2 2024): 44 published measures, 124 facts as tagged in accession 0001628280-24-036529.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-09
Fiscal period
fiscal Q2 2024
Accession
0001628280-24-036529 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cumberland Pharmaceuticals Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-3078,519,175USD
At 2023-12-3181,776,075USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-3052,486,991USD
At 2023-12-3152,516,206USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-3026,348,990USD
At 2023-12-3129,603,441USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-06-3017,336,446USD
At 2023-12-3118,321,624USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1,085,612USD91
2024-01-01 to 2024-06-30-3,031,875USD182
2023-04-01 to 2023-06-30872,200USD91
2023-01-01 to 2023-06-301,064,384USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-2,992,307USD182
2023-01-01 to 2023-06-303,817,152USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-06-3048,799USD182
2023-01-01 to 2023-06-30179,453USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-04-01 to 2024-06-309,848,849USD91
2024-01-01 to 2024-06-3018,346,550USD182
2023-04-01 to 2023-06-3010,888,877USD91
2023-01-01 to 2023-06-3020,113,515USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-06-302,112,119USD182
2023-01-01 to 2023-06-30-5,054,775USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-104,990USD182
2023-01-01 to 2023-06-30-271,261USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-20,520,036USD
At 2023-12-31-17,488,161USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-3014,118,091shares91
2024-01-01 to 2024-06-3014,107,852shares182
2023-04-01 to 2023-06-3014,393,711shares91
2023-01-01 to 2023-06-3014,376,260shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-3014,118,091shares91
2024-01-01 to 2024-06-3014,107,852shares182
2023-04-01 to 2023-06-3014,554,264shares91
2023-01-01 to 2023-06-3014,570,798shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-06-30-0.21USD/shares182
2023-04-01 to 2023-06-300.06USD/shares91
2023-01-01 to 2023-06-300.07USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-06-30-0.21USD/shares182
2023-04-01 to 2023-06-300.06USD/shares91
2023-01-01 to 2023-06-300.07USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-04-01 to 2024-06-3011,443USD91
2024-01-01 to 2024-06-3022,885USD182
2023-04-01 to 2023-06-306,937USD91
2023-01-01 to 2023-06-3013,875USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-06-30337,089USD
At 2023-12-31367,903USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-06-30150,712USD182
2023-01-01 to 2023-06-30188,034USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1,026,688USD91
2024-01-01 to 2024-06-30-2,895,938USD182
2023-04-01 to 2023-06-3022,859USD91
2023-01-01 to 2023-06-30-1,508,819USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-3035,581,093USD
At 2023-12-3135,714,410USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-04-01 to 2024-06-30126,347USD91
2024-01-01 to 2024-06-30244,873USD182
2023-04-01 to 2023-06-30192,635USD91
2023-01-01 to 2023-06-30378,988USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-3024,756,169USD
At 2023-12-3127,982,249USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-06-3012,508,026USD
At 2023-12-3114,037,629USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2024-06-30914,000USD
At 2023-12-31914,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-06-3020,458,835USD
At 2023-12-3122,607,918USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-06-3011,619,763USD
At 2023-12-319,758,176USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2024-01-01 to 2024-06-30381,851USD182
2023-01-01 to 2023-06-30349,910USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-06-304,302,159USD
At 2023-12-314,609,362USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,059,187USD91
2024-01-01 to 2024-06-302,217,440USD182
2023-04-01 to 2023-06-301,145,038USD91
2023-01-01 to 2023-06-302,644,708USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-3014,083,183shares
At 2023-12-3114,121,833shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-3017,336,446USD
At 2023-12-3118,321,624USD
At 2023-06-3018,249,086USD
At 2022-12-3119,757,970USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2024-06-3026,032,184USD
At 2024-03-3127,189,552USD
At 2023-12-3129,259,869USD
At 2023-06-3036,836,902USD
At 2023-03-3136,048,487USD
At 2022-12-3135,974,006USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-06-306,365,790USD
At 2023-12-316,674,394USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-06-305,477,040USD
At 2023-12-315,644,339USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-06-302,993,881USD
At 2023-12-312,692,921USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-06-306,538,970USD
At 2023-12-316,453,566USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-06-302,322,725USD
At 2023-12-313,025,248USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1,091,194USD91
2024-01-01 to 2024-06-30-2,982,224USD182
2023-04-01 to 2023-06-30869,091USD91
2023-01-01 to 2023-06-301,048,315USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-1,102,637USD91
2024-01-01 to 2024-06-30-3,005,109USD182
2024-01-01 to 2024-03-31-1,902,472USD91
2023-04-01 to 2023-06-30862,154USD91
2023-01-01 to 2023-06-301,034,440USD181
2023-01-01 to 2023-03-31172,286USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-302,757,148USD91
2024-01-01 to 2024-06-305,125,055USD182
2023-04-01 to 2023-06-302,369,883USD91
2023-01-01 to 2023-06-304,868,876USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-01-01 to 2024-06-302,290,130USD182
2023-01-01 to 2023-06-302,456,590USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,099,857USD91
2024-01-01 to 2024-06-302,210,518USD182
2023-04-01 to 2023-06-301,158,248USD91
2023-01-01 to 2023-06-302,388,319USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-06-301,861,587USD182
2023-01-01 to 2023-06-30-944,925USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-1,243,245USD182
2023-01-01 to 2023-06-30232,110USD181

Inspect the source

Entity
Cumberland Pharmaceuticals Inc. / CIK 0001087294
Captured
2026-09-20T05:21:29.619Z
SEC response SHA-256
b37ed2fef35db1cde0c40b2233eb97cf370fc96d41a5c7d61b6a5a76a296e4a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001087294.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))